Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by DJDawgon Nov 28, 2024 5:08pm
193 Views
Post# 36336364

Criteria for BTD - hoping we can sell it on the last bullet

Criteria for BTD - hoping we can sell it on the last bullet

Requirements for breakthrough therapy designation 

To qualify for this designation, a therapy must meet two primary criteria: 

  • The therapy must target a disease or condition with significant morbidity or mortality rates. YES
  • Early clinical data should indicate that the therapy offers substantial improvement over available therapies on one or more clinically significant endpoints. SORT OF

Substantial improvement in treatments is characters by three key factors: 

  • Efficacy, where the new treatment demonstrates better effectiveness than existing options.SORT OF
  • Enhanced safety, with fewer or less severe side effects. YES
  • A novel mechanism of action, particularly in addressing unmet medical needs. YES. This is the big one to me. One or two and done is an unmet need for rural and travelling patients. Mechanism is very novel.


<< Previous
Bullboard Posts
Next >>